# ADETERA > ADETERA is a Boston-based scientific-computing company delivering tailored modeling and data-analysis systems for pharmaceutical research and development and chemistry, manufacturing and controls (CMC). Its four X-Platforms are PlateX, CardiX, SolveX and CrystallicX. They connect scientific evidence to screening, nonclinical cardiac assessment, solvent-process development, crystallization and active pharmaceutical ingredient (API) isolation decisions. Company: ADETERA LLC. Official website: https://adetera.com/. Public business and privacy contact: contact@adetera.com. Location described on the website: Boston, Massachusetts, United States. Public website language: English. ADETERA delivers scoped studies, standalone systems, optimized methods, automated workflows and integrations, according to the scientific question and available evidence. Its mathematical models, specialized methods and implementation know-how are proprietary. Public descriptions explain applications and evidence, not model code or confidential client data. The selected anonymized cases represent a small part of ADETERA's work, not its complete application range. Evidence context matters: measured observations, reconstructed signals, AI-predicted inputs, model outputs and conceptual illustrations are different kinds of information. Cellular action-potential duration (APD) is not an ECG QT measurement. A modeled scenario or a prioritized candidate is not a demonstration of clinical safety, an approved dose, or proof of clinical causation. Reported qualitative comparison results are not clinical predictive accuracy. ## Company and working with ADETERA - [ADETERA homepage](https://adetera.com/): Company overview, the four-platform portfolio, development decisions, approach and contact form. - [About ADETERA](https://adetera.com/company/): Who ADETERA supports, its scientific scope, project workflow, delivery options, public evidence and business identity. - [Contact ADETERA](https://adetera.com/#contact): Discuss a scientific question, available data and the decision or workflow the project needs to support. Email contact@adetera.com. - [Official ADETERA LinkedIn page](https://www.linkedin.com/company/adetera): The company's professional profile. ## Scientific platforms - [PlateX — plate analytics and signal analysis](https://adetera.com/platforms/platex/): Plate mapping, well-level experimental context, reader-data import and collection, analysis automation, high-throughput screening (HTS), endpoint and kinetic assays, time-series and dose-response analysis. Scope includes baseline/drift correction, conventional filtering, adaptive denoising, peak separation and alignment, event detection, waveform characterization, very low signal-to-noise ratio (SNR) investigation, false-call assessment and historical screening-data reanalysis. For screening, assay-development and laboratory data-analysis teams; instrument compatibility and confirmation criteria are assessed for the project. - [CardiX — cardiac safety and electrophysiology modeling](https://adetera.com/platforms/cardix/): Tailored in silico cardiac assessment using available hERG, calcium, sodium and other ion-channel evidence. Concentration-response inputs and IC50 uncertainty connect to multichannel effects, virtual cardiac-cell families, action-potential duration, repolarization, early afterdepolarizations (EADs), robustness and stability scenarios, co-medication questions and experimental follow-up. For discovery, safety pharmacology and development teams. Cellular outputs help frame QT-related questions but do not establish a patient's ECG response or arrhythmia risk. - [SolveX — solvent and mixture selection](https://adetera.com/platforms/solvex/): Small-molecule solvent screening considered with the intended process rather than solubility alone. Single-solvent and mixed-solvent systems, temperature and composition context, solvent exchange or solvent swap, distillation-based recovery routes, antisolvent selection, strong solvent interactions, solvate concerns, preliminary crystallization and yield/recovery objectives. For process chemistry and CMC development teams. Proposed routes and recovery expectations require material-specific experimental verification. - [CrystallicX — crystallization, particle engineering and API isolation](https://adetera.com/platforms/crystallicx/): Phase behavior and stability regions, supersaturation, nucleation and growth, diffusion/mass-transfer versus surface-integration or mixed growth control, crystallization strategy, seeding and tailored temperature or dissolution-growth cycles. Particle-size distribution (PSD), crystal habit and particle-shape distribution connect to filterability, cake formation, washing, deliquoring, drying, millability, micronization, flowability, storage and preformulation. An independent platform that can continue SolveX solvent-system work, with or without process analytical technology (PAT). ## Selected PlateX use cases - [Use-case directory](https://adetera.com/use-cases/): Business-first, anonymized examples grouped by PlateX and CardiX, with detailed challenge, approach and outcome narratives. These are selected examples, not the limits of platform scope. - [Intensity-dependent noise and assay consistency](https://adetera.com/use-cases/platex-intensity-dependent-noise/): Nominally matched wells produced inconsistent multi-peak statistics. Analysis of asymmetric, intensity-dependent noise and adaptive correction supported consistent control observations and stable calibration responses. - [Separating main pulses and after-pulses](https://adetera.com/use-cases/platex-overlapping-pulses/): Adaptive denoising and model-informed separation of overlapping events supported reconstruction of main and secondary waveforms and separate concentration-dependent event and shape statistics. - [Legacy plate mapping, adaptive denoising and event analysis](https://adetera.com/use-cases/platex-legacy-plate-data/): A fragmented historical archive was reorganized by well context, families and concentrations, then processed with adaptive denoising and specialized event detection to enable cross-study statistical comparison. - [Cardiac signal reconstruction from noisy proxy recordings](https://adetera.com/use-cases/platex-cardiac-signal-reconstruction/): An assay-appropriate, model-informed cellular action-potential reconstruction from a measured derivative-like or instrument proxy. Separately measured hERG current is distinct evidence. The work supported repolarization and concentration-dependent analysis and identified questions for possible CardiX follow-up; it does not integrate hERG current into an action potential or establish clinical QT effects. - [Extreme SNR — low-SNR ion-channel burst analysis](https://adetera.com/use-cases/platex-extreme-snr/): Statistical denoising was assessed first on a reference dataset with known outcomes, then applied to difficult client recordings to recover burst/event statistics for drug-candidate decisions. Generic true/false-positive and true/false-negative definitions in the illustration are not measured performance results. ## Selected CardiX use cases - [Compare a drug question across virtual cell families](https://adetera.com/use-cases/cardix-virtual-cell-families/): Available hERG potency evidence was used to examine concentration-dependent responses in three tailored virtual cardiac-cell families. Baseline cell-family characteristics and channel potency remain separately defined inputs. - [Examine effects beyond hERG alone](https://adetera.com/use-cases/cardix-multichannel-effects/): Matched concentration scenarios compare hERG-only inputs with combined hERG, calcium and sodium channel evidence. Model-dependent changes in action potentials, repolarization and EAD-related behavior help prioritize follow-up; the example does not establish a universal ranking of channel combinations. - [Investigate a cardiac concern in a co-medication context](https://adetera.com/use-cases/cardix-co-medication-risk/): A retrospective study compares the study compound alone with co-medication scenarios after a clinical concern. Combined channel effects provide mechanistic hypotheses for targeted confirmation, not proof that co-medication caused an individual patient's outcome. - [Prioritize AI-proposed candidates before laboratory testing](https://adetera.com/use-cases/cardix-ai-candidate-prioritization/): AI-predicted hERG IC50 inputs, anticipated concentrations and input uncertainty were used to compare five proposed candidates and prioritize one for the next experiment. Predictions are not laboratory measurements; the selection does not establish a safe dose or clinical safety. ## CardiX evidence and validation report - [CardiX Validation Report](https://adetera.com/platforms/cardix/validation/): Source-linked comparisons across 88 compounds and 98 study runs. The report classifies 59 compounds as full, 20 as partial and 9 as unmatched qualitative comparisons; 79/88 (89.8%) full or partial qualitative effect agreement is not clinical predictive accuracy. Compound detail tables retain numerical source observations, endpoint labels and literature context. Blue experimental triangles/SEM and gold modeled medians/IQR identify distinct evidence; the detailed report explains where comparisons agree and differ. The same report supports a compact cards view using ?view=cards. ## Optional - [Extended ADETERA text reference](https://adetera.com/llms-full.txt): A longer, source-linked text companion containing public company, platform and selected-case narratives and FAQs, plus the validation report's scope and interpretation limits. The linked HTML pages remain the primary published context. - [Privacy & Cookies](https://adetera.com/privacy.html): Website inquiries, technical delivery, submission-abuse controls, current cookie/browser-storage practices and privacy contact. - [XML sitemap](https://adetera.com/sitemap.xml): Canonical public pages available for discovery. Crawler access is described separately in robots.txt; this text guide does not change access permissions or search-engine requirements.